ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 975,63
-0,28%
Dow Jones
38 580,43
0,02%
DAX
18 508,98
-0,54%
Brent Oil
76,765
-1,76%
Bitcoin
69 628,38
1,20%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Centessa Pharmaceuticals PLC (CNTA)

  7. Centessa Pharmaceuticals PLC (CNTA) Actualités

CNTA

Centessa Pharmaceuticals (CNTA)

Centessa Pharmaceuticals PLC
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CNTA
DateHeureSourceTitreSymboleSociété
21/05/202414h45GlobeNewswire Inc.Centessa Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:CNTACentessa Pharmaceuticals PLC
13/05/202422h32Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CNTACentessa Pharmaceuticals PLC
13/05/202422h23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTACentessa Pharmaceuticals PLC
13/05/202422h10GlobeNewswire Inc.Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024NASDAQ:CNTACentessa Pharmaceuticals PLC
09/05/202414h01Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CNTACentessa Pharmaceuticals PLC
09/05/202414h00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CNTACentessa Pharmaceuticals PLC
24/04/202403h36GlobeNewswire Inc.Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary SharesNASDAQ:CNTACentessa Pharmaceuticals PLC
23/04/202422h17GlobeNewswire Inc.Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary SharesNASDAQ:CNTACentessa Pharmaceuticals PLC
22/04/202413h00GlobeNewswire Inc.Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024NASDAQ:CNTACentessa Pharmaceuticals PLC
28/03/202421h28GlobeNewswire Inc.Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023NASDAQ:CNTACentessa Pharmaceuticals PLC
22/02/202414h00GlobeNewswire Inc.Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care ConferenceNASDAQ:CNTACentessa Pharmaceuticals PLC
09/02/202413h00GlobeNewswire Inc.Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia andNASDAQ:CNTACentessa Pharmaceuticals PLC
02/02/202423h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
01/02/202422h07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
13/12/202314h00GlobeNewswire Inc.Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare ConferenceNASDAQ:CNTACentessa Pharmaceuticals PLC
10/12/202318h05GlobeNewswire Inc.Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of HemophiliaNASDAQ:CNTACentessa Pharmaceuticals PLC
27/11/202322h15GlobeNewswire Inc.Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa PharmaceuticalsNASDAQ:CNTACentessa Pharmaceuticals PLC
13/11/202322h05GlobeNewswire Inc.Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023NASDAQ:CNTACentessa Pharmaceuticals PLC
02/11/202314h09GlobeNewswire Inc.Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual MeetingNASDAQ:CNTACentessa Pharmaceuticals PLC
31/10/202313h00GlobeNewswire Inc.Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with InhibitorsNASDAQ:CNTACentessa Pharmaceuticals PLC
25/10/202314h00GlobeNewswire Inc.Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake DisordersNASDAQ:CNTACentessa Pharmaceuticals PLC
03/10/202314h00GlobeNewswire Inc.Centessa Pharmaceuticals Announces Additions to Senior Leadership TeamNASDAQ:CNTACentessa Pharmaceuticals PLC
31/08/202314h00GlobeNewswire Inc.Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceNASDAQ:CNTACentessa Pharmaceuticals PLC
23/08/202323h08GlobeNewswire Inc.Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep CongressNASDAQ:CNTACentessa Pharmaceuticals PLC
14/08/202313h00GlobeNewswire Inc.Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023NASDAQ:CNTACentessa Pharmaceuticals PLC
10/07/202314h00GlobeNewswire Inc.Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without InhibitorsNASDAQ:CNTACentessa Pharmaceuticals PLC
23/06/202323h11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNTACentessa Pharmaceuticals PLC
23/06/202323h02Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:CNTACentessa Pharmaceuticals PLC
22/06/202322h06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CNTACentessa Pharmaceuticals PLC
01/06/202322h46Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:CNTACentessa Pharmaceuticals PLC
 Showing the most relevant articles for your search:NASDAQ:CNTA

Dernières Valeurs Consultées

NYSE
LXP-D.CL
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés